D3.190 - Follow up cases of subcutaneous allergen Immunotherapy in respiratory allergic diseases continuing for 10-30years “A Real life experience of 14 cases”

Background: Allergen immnunotherapy (AIT) is one of treatment options for allergic respiratory diseases with prominent result. The usual recommended duration of AIT is 3-5years. Here we are presenting 14 cases allergic rhinitis (AR) and/or bronchial asthma (BA), those have continuing subcutaneous AIT for 10-30years.

Methods: This is retrospectively collected the data of respiratory allergic cases, those had completed at least 10years of AIT. The data consist of demographic profile, diagnosis, pattern of allergic sensitization, allergen of immunotherapy, duration of AIT and reason of continuation of therapy. As per department protocol we are continuing the AIT in patients who are not willing to stop AIT after3-5yearscourse.

Result: The study consist of 14 cases including 12 BA with AR and two AR. The mean age of study population was 32.75±7.54years with 7(50%) male and 7(50%) female. All cases are polysensitized and immunotherapy with mixed allergen. The symptoms improvement was >80% in 12(86%) and 50-80% in 2(14%) cases. Medication score was decreased in all cases with 12(86%) cases taking on SOS basis with only two cases on regular inhaler that too decreased dose to >50% of baseline. The duration of treatment was >15years in 7(50%) and 10-15years in reaming 7cases. The longest duration was 30 years in two cases. The treatment was continuous in 11(79%) and intermittent in 3(21%) cases. The common reasons for continuation of AIT were symptoms control, medication Score, better QOL, no side effect and fear of exacerbation. (Table 1)

Conclusion: Continuation of subcutaneous AIT is well tolerated for 10-30years in respiratory allergic diseases without any side effect with good control of disease.